Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited: and	
Name of listed issuer:	Green Cross Health Limited
Date this disclosure made:	20/12/2019
Date of last disclosure:	10/06/2013
Date of fact discretifier.	
Director or senior manager giving disclosure	
Full name(s):	John Bolland
Name of listed issuer:	Green Cross Health Limited
Name of related body corporate (if applicable):	N/A
Position held in listed issuer:	Director
Summary of acquisition or disposal of relevant interest (excluding	
specified derivatives)	
Class of affected quoted financial products:	Ordinary shares (NZX: GXH)
	Director and shareholder of former beneficial owner Shawcross Trustee
Nature of the affected relevant interest(s):	Limited (trustee of the Shawcross Trust), which has disposed of its
	beneficial interest in 3,357,557 shares in GHX.
For that relevant interest-	
Number held in class before acquisition or disposal:	3,357,557
Number held in class after acquisition or disposal:	0
Current registered holder(s):	LPL Trustee Limited
Registered holder(s) once transfers are registered:	LPL Trustee Limited
Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)	
Type of affected derivative:	N/A
Class of underlying financial products:	N/A
Details of affected derivative-	
The notional value of the derivative (if any) or the notional amount of	
underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically	IV/A
settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price specified in the terms of the derivative (if any):	N/A
The price specified in the terms of the derivative (is any).	IVA
Any other details needed to understand how the amount of the	
consideration payable under the derivative or the value of the derivative	
is affected by the value of the underlying financial products:	N/A
For that derivative,-	[1473
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the	17/7
nature of the relevant interest in the derivative:	N/A
riature of the relevant interest in the derivative.	[137]
Details of transactions giving rise to acquisition or disposal	
Total number of transactions to which notice relates:	1
Total number of Harisactions to Willoft Hotice Telates.	

Details of transactions requiring disclosure-	
Date of transaction:	20/12/2019
Nature of transaction:	John Bolland has resigned as a director of LPL Trustee Limited.
	Pursuant an agreement dated 9 June 2013 (the Agreement), Shawcross
	Trustee Limited (trustee of the Shawcross Trust) acquired a beneficial
	interest (but not voting rights) in 3,357,557 ordinary shares (the Shares)
	in Green Cross Health Limited legally held by LPL Trustee Limited (as
	trustee of LPL Trust). On 18 December 2019, Shawcross Trustee
	Limited and LPL Trustee Limited executed a sale and purchase
	agreement whereby LPL Trustee Limited acquired back beneficial title to
	the Shares, and following completion under that agreement Shawcross
	Trustee Limited has no relevant interest in the Shares or any ability to
	control or influence that shareholding.
Name of any other party or parties to the transaction (if known):	LPL Trustee Limited; Shawcross Trustee Limited.
The consideration, expressed in New Zealand dollars, paid or received	
for the acquisition or disposal. If the consideration was not in cash and	
cannot be readily by converted into a cash value, describe the	
consideration:	\$4,615,969
Number of financial products to which the transaction related:	3,357,557
If the issuer has a financial products trading policy that prohibits	
directors or senior managers from trading during any period without	
written clearance (a closed period) include the following details—	
Whether relevant interests were acquired or disposed of during a closed	
period:	Yes
Whether prior written clearance was provided to allow the acquisition or	
disposal to proceed during the closed period:	Yes
Date of the prior written clearance (if any):	N/A
Summary of other relevant interests after acquisition or disposal:	
Summary of other relevant interests after acquisition of disposal.	
Class of quoted financial products:	N/A
Nature of relevant interest:	N/A
For that relevant interest,-	
Number held in class:	N/A
Current registered holder(s):	N/A
For a derivative relevant interest,-	
Type of derivative:	N/A
Details of derivative,-	
The notional value of the derivative (if any) or the notional amount of	
underlying financial products (if any):	N/A
A statement as to whether the derivative is cash settled or physically	
settled:	N/A
Maturity date of the derivative (if any):	N/A
Expiry date of the derivative (if any):	N/A
The price's specified terms (if any):	N/A
Any other details needed to understand how the amount of the	
consideration payable under the derivative or the value of the derivative	
is affected by the value of the underlying financial products:	
-	N/A
For that derivative relevant interest,-	N/A
Parties to the derivative:	N/A
If the director or senior manager is not a party to the derivative, the	
nature of the relevant interest in the derivative:	N/A
	/ /
Certification	1 Landerson
I, certify that, to the best of my knowledge and belief, the information	1410
contained in this disclosure is correct and that I am duly authorised to	IN
make this disclosure by all persons for whom it is made.	
Signature of director or officer:	20140/2010
Date of signature:	20/12/2019